ClinicalTrials.gg
Active, not recruitingNCT05440786Updated Oct 20, 2026Results posted

CAMPFIRE: A Study of Abemaciclib (LY2835219) in Participants With Ewing's Sarcoma

A Phase 2 interventional study of Abemaciclib and Irinotecan in Sarcoma, Ewing and Neoplasm Metastasis, sponsored by Eli Lilly and Company. Active, not recruiting at 29 sites in 7 countries. Open to participants aged 1 Year to 39 Years. Per ClinicalTrials.gov, last updated 2026-10-20.

Sponsored by Eli Lilly and Company · Phase 2, Interventional, and Treatment

Updated Oct 20, 2026Study completion movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
46
Allocation
Randomized
Ages
1 Year to 39 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 14 studies testing irinotecan in Sarcoma, Ewing — 4 open to participants now, 6 under way, none of them phase 3. Irinotecan · Sarcoma, Ewing.

Enrollment
3rd of 14
46 · median 31
Started
2022
the only one that year
Phase 2
6 of 14
1 open now
Registered
10th of 14
by date
Lead sponsor
1 of 14
Eli Lilly and Company

Among the 14 studies testing irinotecan in Sarcoma, Ewing, this one is the 3rd largest by enrollment, is the only one that started in 2022, is one of 6 in phase 2, and was the 10th registered.

Sarcoma, Ewing

250 studies on the registry are indexed under Sarcoma, Ewing; 69 are open to participants now.

Browse Sarcoma, Ewing studies →

Open to participants now

4 of the 14 studies testing irinotecan in Sarcoma, Ewing are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

About irinotecan

Irinotecan: first FDA approval 1996 (CAMPTOSAR), first EMA approval 2016. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 58 Sarcoma, Ewing studies recruiting now, 19 (33%) set no upper age limit and 36 (62%) stop at 75 or younger; 49 take children under 18; 2 take healthy volunteers.

This study: 1 Year to 39 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 14 studies testing irinotecan in Sarcoma, Ewing, or all of them as a file.
02

Study summary

The purpose of this study is to measure the benefit of adding abemaciclib to chemotherapy (irinotecan and temozolomide) for Ewing's sarcoma that has come back or did not respond to treatment. This trial is part of the CAMPFIRE master protocol, which is a platform to speed development of new treatments for children and young adults with cancer. Your participation in this trial could last 11 months or longer, depending on how you and your tumor respond.

03

Conditions studied

  • Sarcoma, Ewing
  • Neoplasm Metastasis
04

Who can participate

Ages eligible
1 Year to 39 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosis of Ewing's sarcoma or Ewing's sarcoma-like tumor by institutional pathologist. The original pathological report is required. Repeat at progression is not required
  • disease or confirmed radiological progression or recurrence following first or of treatment of Ewing's sarcoma or Ewing's sarcoma-like tumor

    -- Must have one measurable or evaluable lesion per 1.1

  • Adequate performance status based on age

    • For participants less than (\<)16 years of age, a Lansky score greater than or equal to (≥)50, or
    • For participants ≥16 years of age, a score ≥50
  • Participants must have discontinued all previous treatments for cancer or agents ≥7 days after the last dose and must have recovered from the acute effects
  • Adequate hematologic and organ function less than or equal to (≤)14 days prior to Day 1 of Cycle 1:

    • ≥1000/microliter (µL)
    • ≥75,000/cubic millimeter (mm³)
    • ≥8 grams per deciLiter (g/Dl) (≥100 grams per Liter [g/L])
    • Total ≤1.5 times (×) (ULN)
    • (AST) and alanine aminotransferase (ALT) ≤3 × ULN
    • or calculated (GFR) ≥60 milliliters per minute per square meter (Ml/min/m²) or serum creatinine based on age/gender
  • Female participants of must have a negative urine or serum pregnancy test
  • Body weight ≥10 kilograms (kg)
  • Must be able to swallow and/or have a gastric/nasogastric tube

    -- Participants in the European Union must be able to swallow intact capsules

  • Stable or decreasing dose of at least 7 days prior to enrollment
  • of at least 8 weeks and able to complete at least 1 cycle of treatment
  • Participants/caregivers are able and willing to make themselves available for the duration of the study and are willing to follow study procedures, including adherence to the pharmacokinetic (PK) sampling schedule

Exclusion criteria

Exclusion Criteria:

  • Participants with severe and/or uncontrolled concurrent medical disease or psychiatric illness/social situation that in the opinion of the investigator could cause unacceptable safety risks or compromise compliance with the protocol
  • Participants with an active fungal, bacterial, and/or known severe viral infection including, but not limited to, (HIV) or viral (A, B, or C) hepatitis.
  • Participants who have had allogeneic bone marrow or solid organ transplant
  • Surgery: Participants who have had, or are planning to have, the following invasive procedures:

    • Major surgical procedure, laparoscopic procedure, or significant traumatic injury within 28 days prior to enrollment
    • Surgical or other wounds must be adequately healed prior to enrollment
  • Female participants who are pregnant or breastfeeding
  • Have received any prior cyclin-dependent kinase (CDK) 4 and 6 inhibitor
  • Progression during prior treatment with irinotecan and/or temozolomide
  • Have a known intolerability or to any of the study treatments or dacarbazine
  • Diagnosed and/or treated additional within 3 years prior to enrollment
Terms in these criteria, in plain language(20)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Karnofsky performance status (KPS)

A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.

Studies often ask for 60 or 70 and above. Your doctor gives the score.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
46 participants (actual)

Study arms

  • Experimental
    Abemaciclib + Irinotecan +Temozolomide

    Participants received the following treatments in a 21-day cycle, continuing until disease progression, unacceptable toxicity, or a criterion for discontinuation was met. * Abemaciclib: 55 mg/m² (milligrams per square meter), administered orally twice daily (BID) for less than (\<18) years or 100 mg administered orally BID for greater than or equal to (≥)18 years. * Irinotecan: 50 mg/m²/day, administered intravenously (IV) on Days 1-5 of each cycle. * Temozolomide: 100 mg/m²/day, administered orally on Days 1-5 of each cycle.

    Drug: Abemaciclib · Drug: Irinotecan · Drug: Temozolomide

  • Experimental
    Irinotecan +Temozolomide

    Participants received the following treatments in a 21-day cycle, continuing until disease progression, unacceptable toxicity, or a criterion for discontinuation was met. * Irinotecan: 50 mg/m²/day, administered IV on Days 1-5 of each cycle. * Temozolomide: 100 mg/m²/day, administered orally on Days 1-5 of each cycle.

    Drug: Irinotecan · Drug: Temozolomide

Interventions

06

What researchers measure

Primary outcomes

  1. Progression Free Survival (PFS) Assessed by Blinded Independent Review Committee (BIRC) by Bayesian Analysis

    PFS was defined as the time from randomization until the first occurrence of documented disease progression per Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v1.1) criteria, or death from any cause in absence of progressive disease, whichever came first. Progressive disease (PD) was defined as at least 20% increase in the sum of the diameters of target lesions, with reference being the smallest sum on study and an absolute increase of at least 5 millimeter (mm), or unequivocal progression of non-target lesions, or 1 or more new lesions. An event was considered when tumor progression or death occurred, with event date being the earliest date of PD or death. Participants known to be alive and without tumor progression were censored at date of their last adequate tumor assessment per RECIST v1.1 criteria, or date of randomization (whichever was later). Results were obtained using Bayesian analysis and are reported as posterior mean along with its 80% credible interval.

    Time frame: From Date of Randomization until Disease Progression or Death Due to Any Cause (Up to 22.36 months)

  2. PFS Assessed by BIRC by Frequentist Analysis

    PFS was defined as the time from randomization until the first occurrence of documented disease progression per RECIST v1.1 criteria, or death from any cause in absence of progressive disease, whichever came first. PD was defined as at least 20% increase in the sum of the diameters of target lesions, with reference being the smallest sum on study and an absolute increase of at least 5 mm, or unequivocal progression of non-target lesions, or 1 or more new lesions. An event was considered when tumor progression or death occurred, with the event date being the earliest date of PD or death. Participants known to be alive and without tumor progression were censored at the date of their last adequate tumor assessment per RECIST v1.1 criteria, or date of randomization (whichever was later). Results were obtained using frequentist analysis.

    Time frame: From Date of Randomization until Disease Progression or Death Due to Any Cause (Up to 22.36 months)

Secondary outcomes

  1. PFS Assessed by Investigator by Bayesian Analysis

    PFS was defined as the time from randomization until the first occurrence of documented disease progression per RECIST v1.1 criteria, or death from any cause in absence of progressive disease, whichever came first. PD was defined as at least a 20% increase in the sum of diameters of target lesions, with reference being the smallest sum on study and an absolute increase of at least 5 mm, or unequivocal progression of non-target lesions, or 1 or more new lesions. An event was considered when tumor progression or death occurred, with the event date being the earliest date of PD or death. Participants known to be alive and without tumor progression were censored at the date of their last adequate tumor assessment per RECIST v1.1 criteria, or date of randomization (whichever was later). Results were obtained using Bayesian analysis and are reported as posterior mean along with its 80% credible interval.

    Time frame: From Date of Randomization until Disease Progression or Death Due to Any Cause (Up to 22.39 Months)

  2. PFS Assessed by Investigator by Frequentist Analysis

    PFS was defined as the time from randomization until the first occurrence of documented disease progression per RECIST v1.1 criteria, or death from any cause in absence of progressive disease, whichever came first. PD was defined as at least a 20% increase in the sum of diameters of target lesions, with reference being the smallest sum on study and an absolute increase of at least 5 mm, or unequivocal progression of non-target lesions, or 1 or more new lesions. An event was considered when tumor progression or death occurred, with the event date being the earliest date of PD or death. Participants known to be alive and without tumor progression were censored at the date of their last adequate tumor assessment per RECIST 1.1 criteria, or date of randomization (whichever was later). Results were obtained using frequentist analysis.

    Time frame: From Date of Randomization until Disease Progression or Death Due to Any Cause (Up to 22.39 Months)

  3. Overall Survival (OS)

    OS was defined as the time from date of randomization until death from any cause. If the participant was alive or lost to follow-up at the time of data analysis, OS data were censored on the last date the participant was known to be alive.

    Time frame: From Date of Randomization until Death Due to Any Cause (Up to 26.37 months)

  4. Overall Response Rate (ORR): Percentage of Participants Who Achieved a Complete Response (CR) or Partial Response (PR) Assessed by BIRC

    ORR was defined as the number of participants who achieved the best overall response of complete response (CR) or partial response (PR) as per RECIST v1.1 criteria. CR defined as the disappearance of all target and non-target lesions and no appearance of new lesions. PR defined as at least a 30% decrease in the sum of the longest diameters of target lesions (taking as reference the baseline sum LD), no progression of non-target lesions, and no appearance of new lesions.

    Time frame: From Date of Randomization until Disease Progression, Death Due to Any Cause, Concomitant Radiotherapy/Surgery, or Start of New Anti-Cancer Therapy (Up to 22.36 Months)

  5. ORR: Percentage of Participants Who Achieved a CR or PR Assessed by Investigator

    ORR was defined as the number of participants who achieved the best overall response of CR or PR as per RECIST v1.1 criteria. CR defined as the disappearance of all target and non-target lesions and no appearance of new lesions. PR defined as at least a 30% decrease in the sum of the longest diameters of target lesions (taking as reference the baseline sum LD), no progression of non-target lesions, and no appearance of new lesions.

    Time frame: From Date of Randomization until Disease Progression, Death Due to Any Cause, Concomitant Radiotherapy/Surgery, or Start of New Anti-Cancer Therapy (Up to 22.39 Months)

  6. Duration of Response (DoR) Assessed by BIRC

    DoR was defined as the time from the date that measurement criteria for CR or PR (whichever was first recorded) were first met until the first date that recurrent disease or documented disease progression was observed per RECIST v1.1 criteria, or the date of death from any cause in the absence of documented disease progression or recurrence. DoR was calculated for participants with only PR or CR. CR was defined as the disappearance of all target and non-target lesions and no appearance of new lesions. PR was defined as at least a 30% decrease in the sum of the longest diameters (LD) of target lesions (taking as reference the baseline sum LD), no progression of non-target lesions, and no appearance of new lesions. Participants with an observed CR or PR, no confirmed disease progression per RECIST v1.1 criteria, and no death due to any cause were censored at the time of the last adequate post-baseline scan.

    Time frame: From Date of CR, PR until Disease Progression or Death Due to Any Cause (Up to 10.7 Months)

  7. DoR Assessed by Investigator

    DoR was defined as the time from the date that measurement criteria for CR or PR (whichever was first recorded) were first met until the first date that recurrent disease or documented disease progression was observed, per RECIST v1.1 criteria, or the date of death from any cause in the absence of documented disease progression or recurrence. DoR was calculated for participants with only PR or CR. CR was defined as the disappearance of all target and non-target lesions and no appearance of new lesions. PR was defined as at least a 30% decrease in the sum of the longest diameters of target lesions (taking as reference the baseline sum LD), no progression of non-target lesions, and no appearance of new lesions. Participants with an observed CR or PR, no confirmed disease progression per RECIST v1.1 criteria, and no death due to any cause were censored at the time of the last adequate post-baseline scan.

    Time frame: From Date of CR, PR until Disease Progression or Death Due to Any Cause (Up to 12.7 Months)

  8. Percentage of Participants With a Best Overall Response of CR, PR, Stable Disease (SD) or Non-CR/Non-PD: Disease Control Rate (DCR) Assessed by BIRC

    Disease control rate (DCR) was the percentage of participants with a best overall response of CR, PR, SD or Non-CR/Non-PD as defined by RECIST v1.1 criteria. CR was defined as the disappearance of all target and non-target lesions and no appearance of new lesions. PR was defined as at least a 30% decrease in the sum of the LD of target lesions (taking as reference the baseline sum LD), no progression of non-target lesions, and no appearance of new lesions. SD was neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD for target lesions, no progression of non-target lesions, and no appearance of new lesions. Non-CR/Non-PD was defined as persistence of one or more non-target lesions and/or maintained tumor marker levels, but without sufficient progression to be considered PD and without complete disappearance to be CR.

    Time frame: From Date of Randomization until Disease Progression, or Death Due to Any Cause, Concomitant Radiotherapy/Surgery, or Start of New Anti-Cancer Therapy (Up to 22.36 Months)

  9. Percentage of Participants With a Best Overall Response of CR, PR or SD: DCR Assessed by Investigator

    DCR was the percentage of participants with a best overall response of CR, PR, or SD as defined by RECIST v1.1 criteria. CR was defined as the disappearance of all target and non-target lesions and no appearance of new lesions. PR was defined as at least a 30% decrease in the sum of the LD of target lesions (taking as reference the baseline sum LD), no progression of non-target lesions, and no appearance of new lesions. SD was neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for progressive disease for target lesions, no progression of non-target lesions, and no appearance of new lesions.

    Time frame: From Date of Randomization until Disease Progression, or Death Due to Any Cause, Concomitant Radiotherapy/Surgery, or Start of New Anti-Cancer Therapy (Up to 22.39 Months)

  10. Pharmacokinetics (PK): Minimum Plasma Concentration (Cmin) of Abemaciclib

    PK: Cmin of Abemaciclib were reported.

    Time frame: Pre-dose on Cycle 1 Day 15, Cycle 2 Day 1, Cycle 3 Day 1; End of irinotecan infusion on Cycle 2 Day 1 and Cycle 4 Day 1

  11. Abemaciclib Product Acceptability

    Participants were evaluated for abemaciclib acceptability by asking a question - " Was it easy or difficult for the study participant to swallow the abemaciclib today?" Participants or their caregivers or both could respond using the following possible answers: "Very difficult", "difficult", "neither easy nor difficult", "easy", or "very easy". Acceptability was assessed for formulations: tablets, oral granules, and dispersed tablets.

    Time frame: Day 1 of Cycle 1 through Cycle 3 (21-day cycles)

07

Results

Posted Mar 12, 2026
Limitations and caveats
The Bayesian models for PFS by BIRC and PFS by Investigator assume an exponential distribution for the PFS times, which is more restrictive than the distributional assumptions made by the frequentist Cox proportional hazards model.

Participant flow

Participant flow — Overall Study
MilestoneAbemaciclib + Irinotecan +TemozolomideIrinotecan +Temozolomide
Started3016
Received at least one dose of study drug3015
Completed158
Not completed158
Withdrew: Withdrawal by parent or guardian11
Withdrew: Withdrawal by subject01
Withdrew: Randomized but not treated01
Withdrew: On study (ongoing)145

Outcome measures

PrimaryProgression Free Survival (PFS) Assessed by Blinded Independent Review Committee (BIRC) by Bayesian Analysis

PFS was defined as the time from randomization until the first occurrence of documented disease progression per Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v1.1) criteria, or death from any cause in absence of progressive disease, whichever came first. Progressive disease (PD) was defined as at least 20% increase in the sum of the diameters of target lesions, with reference being the smallest sum on study and an absolute increase of at least 5 millimeter (mm), or unequivocal progression of non-target lesions, or 1 or more new lesions. An event was considered when tumor progression or death occurred, with event date being the earliest date of PD or death. Participants known to be alive and without tumor progression were censored at date of their last adequate tumor assessment per RECIST v1.1 criteria, or date of randomization (whichever was later). Results were obtained using Bayesian analysis and are reported as posterior mean along with its 80% credible interval.

Time frame:
From Date of Randomization until Disease Progression or Death Due to Any Cause (Up to 22.36 months)
Reported as:
Mean · Months
Progression Free Survival (PFS) Assessed by Blinded Independent Review Committee (BIRC) by Bayesian Analysis
MonthsAbemaciclib + Irinotecan +TemozolomideIrinotecan +Temozolomide
Progression Free Survival (PFS) Assessed by Blinded Independent Review Committee (BIRC) by Bayesian AnalysisNA (NA to NA)NA (NA to NA)
Statistical analysis
  • Abemaciclib + Irinotecan +Temozolomide vs Irinotecan +Temozolomide · Bayesian hierarchical model · Posterior mean hazard ratio: 0.530 · 80% CI 0.317 to 0.783
PrimaryPFS Assessed by BIRC by Frequentist Analysis

PFS was defined as the time from randomization until the first occurrence of documented disease progression per RECIST v1.1 criteria, or death from any cause in absence of progressive disease, whichever came first. PD was defined as at least 20% increase in the sum of the diameters of target lesions, with reference being the smallest sum on study and an absolute increase of at least 5 mm, or unequivocal progression of non-target lesions, or 1 or more new lesions. An event was considered when tumor progression or death occurred, with the event date being the earliest date of PD or death. Participants known to be alive and without tumor progression were censored at the date of their last adequate tumor assessment per RECIST v1.1 criteria, or date of randomization (whichever was later). Results were obtained using frequentist analysis.

Time frame:
From Date of Randomization until Disease Progression or Death Due to Any Cause (Up to 22.36 months)
Reported as:
Median · Months
PFS Assessed by BIRC by Frequentist Analysis
MonthsAbemaciclib + Irinotecan +TemozolomideIrinotecan +Temozolomide
PFS Assessed by BIRC by Frequentist Analysis2.79 (1.74 to 13.32)2.89 (1.25 to 5.13)
Statistical analysis
  • Abemaciclib + Irinotecan +Temozolomide vs Irinotecan +Temozolomide · Log Rank · p = 0.281 · Hazard ratio (hr): 0.639 · 95% CI 0.282 to 1.449Hazard ratio estimation stratified by age (≥18 vs \<18 years), time to recurrence, and metastatic status at study entry. Stratification factors were collected via interactive web response system.
SecondaryPFS Assessed by Investigator by Bayesian Analysis

PFS was defined as the time from randomization until the first occurrence of documented disease progression per RECIST v1.1 criteria, or death from any cause in absence of progressive disease, whichever came first. PD was defined as at least a 20% increase in the sum of diameters of target lesions, with reference being the smallest sum on study and an absolute increase of at least 5 mm, or unequivocal progression of non-target lesions, or 1 or more new lesions. An event was considered when tumor progression or death occurred, with the event date being the earliest date of PD or death. Participants known to be alive and without tumor progression were censored at the date of their last adequate tumor assessment per RECIST v1.1 criteria, or date of randomization (whichever was later). Results were obtained using Bayesian analysis and are reported as posterior mean along with its 80% credible interval.

Time frame:
From Date of Randomization until Disease Progression or Death Due to Any Cause (Up to 22.39 Months)
Reported as:
Mean · Months
PFS Assessed by Investigator by Bayesian Analysis
MonthsAbemaciclib + Irinotecan +TemozolomideIrinotecan +Temozolomide
PFS Assessed by Investigator by Bayesian AnalysisNA (NA to NA)NA (NA to NA)
Statistical analysis
  • Abemaciclib + Irinotecan +Temozolomide vs Irinotecan +Temozolomide · Bayesian hierarchical model · Posterior mean hazard ratio: 0.684 · 80% CI 0.412 to 1.010
SecondaryPFS Assessed by Investigator by Frequentist Analysis

PFS was defined as the time from randomization until the first occurrence of documented disease progression per RECIST v1.1 criteria, or death from any cause in absence of progressive disease, whichever came first. PD was defined as at least a 20% increase in the sum of diameters of target lesions, with reference being the smallest sum on study and an absolute increase of at least 5 mm, or unequivocal progression of non-target lesions, or 1 or more new lesions. An event was considered when tumor progression or death occurred, with the event date being the earliest date of PD or death. Participants known to be alive and without tumor progression were censored at the date of their last adequate tumor assessment per RECIST 1.1 criteria, or date of randomization (whichever was later). Results were obtained using frequentist analysis.

Time frame:
From Date of Randomization until Disease Progression or Death Due to Any Cause (Up to 22.39 Months)
Reported as:
Median · Months
PFS Assessed by Investigator by Frequentist Analysis
MonthsAbemaciclib + Irinotecan +TemozolomideIrinotecan +Temozolomide
PFS Assessed by Investigator by Frequentist Analysis2.93 (1.74 to 10.59)3.81 (1.41 to 6.94)
Statistical analysis
  • Abemaciclib + Irinotecan +Temozolomide vs Irinotecan +Temozolomide · Log Rank · p = 0.400 · Hazard ratio (hr): 0.707 · 95% CI 0.316 to 1.582Hazard ratio estimation stratified by age (≥18 vs \<18 years), time to recurrence, and metastatic status at study entry. Stratification factors were collected via interactive web response system.
SecondaryOverall Survival (OS)

OS was defined as the time from date of randomization until death from any cause. If the participant was alive or lost to follow-up at the time of data analysis, OS data were censored on the last date the participant was known to be alive.

Time frame:
From Date of Randomization until Death Due to Any Cause (Up to 26.37 months)
Reported as:
Median · Months
Overall Survival (OS)
MonthsAbemaciclib + Irinotecan +TemozolomideIrinotecan +Temozolomide
Overall Survival (OS)21.21 (9.17 to NA)6.94 (5.13 to NA)
Statistical analysis
  • Abemaciclib + Irinotecan +Temozolomide vs Irinotecan +Temozolomide · Log Rank · p = 0.406 · Hazard ratio (hr): 0.667 · 95% CI 0.255 to 1.745Hazard ratio estimation stratified by age (≥18 vs \<18 years), time to recurrence, and metastatic status at study entry. Stratification factors were collected via interactive web response system.
SecondaryOverall Response Rate (ORR): Percentage of Participants Who Achieved a Complete Response (CR) or Partial Response (PR) Assessed by BIRC

ORR was defined as the number of participants who achieved the best overall response of complete response (CR) or partial response (PR) as per RECIST v1.1 criteria. CR defined as the disappearance of all target and non-target lesions and no appearance of new lesions. PR defined as at least a 30% decrease in the sum of the longest diameters of target lesions (taking as reference the baseline sum LD), no progression of non-target lesions, and no appearance of new lesions.

Time frame:
From Date of Randomization until Disease Progression, Death Due to Any Cause, Concomitant Radiotherapy/Surgery, or Start of New Anti-Cancer Therapy (Up to 22.36 Months)
Reported as:
Number · Percentage of Participants
Overall Response Rate (ORR): Percentage of Participants Who Achieved a Complete Response (CR) or Partial Response (PR) Assessed by BIRC
Percentage of ParticipantsAbemaciclib + Irinotecan +TemozolomideIrinotecan +Temozolomide
Overall Response Rate (ORR): Percentage of Participants Who Achieved a Complete Response (CR) or Partial Response (PR) Assessed by BIRC10.0 (2.1 to 26.5)25.0 (7.3 to 52.4)
SecondaryORR: Percentage of Participants Who Achieved a CR or PR Assessed by Investigator

ORR was defined as the number of participants who achieved the best overall response of CR or PR as per RECIST v1.1 criteria. CR defined as the disappearance of all target and non-target lesions and no appearance of new lesions. PR defined as at least a 30% decrease in the sum of the longest diameters of target lesions (taking as reference the baseline sum LD), no progression of non-target lesions, and no appearance of new lesions.

Time frame:
From Date of Randomization until Disease Progression, Death Due to Any Cause, Concomitant Radiotherapy/Surgery, or Start of New Anti-Cancer Therapy (Up to 22.39 Months)
Reported as:
Number · Percentage of Participants
ORR: Percentage of Participants Who Achieved a CR or PR Assessed by Investigator
Percentage of ParticipantsAbemaciclib + Irinotecan +TemozolomideIrinotecan +Temozolomide
ORR: Percentage of Participants Who Achieved a CR or PR Assessed by Investigator16.7 (5.6 to 34.7)18.8 (4.1 to 45.7)
SecondaryDuration of Response (DoR) Assessed by BIRC

DoR was defined as the time from the date that measurement criteria for CR or PR (whichever was first recorded) were first met until the first date that recurrent disease or documented disease progression was observed per RECIST v1.1 criteria, or the date of death from any cause in the absence of documented disease progression or recurrence. DoR was calculated for participants with only PR or CR. CR was defined as the disappearance of all target and non-target lesions and no appearance of new lesions. PR was defined as at least a 30% decrease in the sum of the longest diameters (LD) of target lesions (taking as reference the baseline sum LD), no progression of non-target lesions, and no appearance of new lesions. Participants with an observed CR or PR, no confirmed disease progression per RECIST v1.1 criteria, and no death due to any cause were censored at the time of the last adequate post-baseline scan.

Time frame:
From Date of CR, PR until Disease Progression or Death Due to Any Cause (Up to 10.7 Months)
Reported as:
Median · Months
Duration of Response (DoR) Assessed by BIRC
MonthsAbemaciclib + Irinotecan +TemozolomideIrinotecan +Temozolomide
Duration of Response (DoR) Assessed by BIRCNA (NA to NA)NA (NA to NA)
SecondaryDoR Assessed by Investigator

DoR was defined as the time from the date that measurement criteria for CR or PR (whichever was first recorded) were first met until the first date that recurrent disease or documented disease progression was observed, per RECIST v1.1 criteria, or the date of death from any cause in the absence of documented disease progression or recurrence. DoR was calculated for participants with only PR or CR. CR was defined as the disappearance of all target and non-target lesions and no appearance of new lesions. PR was defined as at least a 30% decrease in the sum of the longest diameters of target lesions (taking as reference the baseline sum LD), no progression of non-target lesions, and no appearance of new lesions. Participants with an observed CR or PR, no confirmed disease progression per RECIST v1.1 criteria, and no death due to any cause were censored at the time of the last adequate post-baseline scan.

Time frame:
From Date of CR, PR until Disease Progression or Death Due to Any Cause (Up to 12.7 Months)
Reported as:
Median · Months
DoR Assessed by Investigator
MonthsAbemaciclib + Irinotecan +TemozolomideIrinotecan +Temozolomide
DoR Assessed by InvestigatorNA (NA to NA)NA (NA to NA)
SecondaryPercentage of Participants With a Best Overall Response of CR, PR, Stable Disease (SD) or Non-CR/Non-PD: Disease Control Rate (DCR) Assessed by BIRC

Disease control rate (DCR) was the percentage of participants with a best overall response of CR, PR, SD or Non-CR/Non-PD as defined by RECIST v1.1 criteria. CR was defined as the disappearance of all target and non-target lesions and no appearance of new lesions. PR was defined as at least a 30% decrease in the sum of the LD of target lesions (taking as reference the baseline sum LD), no progression of non-target lesions, and no appearance of new lesions. SD was neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD for target lesions, no progression of non-target lesions, and no appearance of new lesions. Non-CR/Non-PD was defined as persistence of one or more non-target lesions and/or maintained tumor marker levels, but without sufficient progression to be considered PD and without complete disappearance to be CR.

Time frame:
From Date of Randomization until Disease Progression, or Death Due to Any Cause, Concomitant Radiotherapy/Surgery, or Start of New Anti-Cancer Therapy (Up to 22.36 Months)
Reported as:
Number · Percentage of Participants
Percentage of Participants With a Best Overall Response of CR, PR, Stable Disease (SD) or Non-CR/Non-PD: Disease Control Rate (DCR) Assessed by BIRC
Percentage of ParticipantsAbemaciclib + Irinotecan +TemozolomideIrinotecan +Temozolomide
Percentage of Participants With a Best Overall Response of CR, PR, Stable Disease (SD) or Non-CR/Non-PD: Disease Control Rate (DCR) Assessed by BIRC60.0 (40.6 to 77.3)50.0 (24.7 to 75.4)
SecondaryPercentage of Participants With a Best Overall Response of CR, PR or SD: DCR Assessed by Investigator

DCR was the percentage of participants with a best overall response of CR, PR, or SD as defined by RECIST v1.1 criteria. CR was defined as the disappearance of all target and non-target lesions and no appearance of new lesions. PR was defined as at least a 30% decrease in the sum of the LD of target lesions (taking as reference the baseline sum LD), no progression of non-target lesions, and no appearance of new lesions. SD was neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for progressive disease for target lesions, no progression of non-target lesions, and no appearance of new lesions.

Time frame:
From Date of Randomization until Disease Progression, or Death Due to Any Cause, Concomitant Radiotherapy/Surgery, or Start of New Anti-Cancer Therapy (Up to 22.39 Months)
Reported as:
Number · Percentage of Participants
Percentage of Participants With a Best Overall Response of CR, PR or SD: DCR Assessed by Investigator
Percentage of ParticipantsAbemaciclib + Irinotecan +TemozolomideIrinotecan +Temozolomide
Percentage of Participants With a Best Overall Response of CR, PR or SD: DCR Assessed by Investigator60.0 (40.6 to 77.3)56.3 (29.9 to 80.3)
SecondaryPharmacokinetics (PK): Minimum Plasma Concentration (Cmin) of Abemaciclib

PK: Cmin of Abemaciclib were reported.

Time frame:
Pre-dose on Cycle 1 Day 15, Cycle 2 Day 1, Cycle 3 Day 1; End of irinotecan infusion on Cycle 2 Day 1 and Cycle 4 Day 1
Reported as:
Geometric mean · nanogram per milliliter
Pharmacokinetics (PK): Minimum Plasma Concentration (Cmin) of Abemaciclib
nanogram per milliliterAbemaciclib + Irinotecan +Temozolomide
Pharmacokinetics (PK): Minimum Plasma Concentration (Cmin) of Abemaciclib118 ± 95
SecondaryAbemaciclib Product Acceptability

Participants were evaluated for abemaciclib acceptability by asking a question - " Was it easy or difficult for the study participant to swallow the abemaciclib today?" Participants or their caregivers or both could respond using the following possible answers: "Very difficult", "difficult", "neither easy nor difficult", "easy", or "very easy". Acceptability was assessed for formulations: tablets, oral granules, and dispersed tablets.

Time frame:
Day 1 of Cycle 1 through Cycle 3 (21-day cycles)
Reported as:
Count of participants · Participants
Abemaciclib Product Acceptability
ParticipantsAbemaciclib (Cycle 1 Day 1)Abemaciclib (Cycle 2 Day 1)Abemaciclib (Cycle 3 Day 1)
Participant Who Received Abemaciclib Tablet: Participant Responses — Very easy to swallow151611
Participant Who Received Abemaciclib Tablet: Participant Responses — Easy to swallow412
Participant Who Received Abemaciclib Tablet: Participant Responses — Neither easy nor difficult to swallow210
Participant Who Received Abemaciclib Tablet: Participant Responses — Difficult to swallow100
Participant Who Received Abemaciclib Tablet: Participant Responses — Very difficult to swallow000
Participant Who Received Abemaciclib Tablet: Caregiver Responses — Very easy to swallow574
Participant Who Received Abemaciclib Tablet: Caregiver Responses — Easy to swallow101
Participant Who Received Abemaciclib Tablet: Caregiver Responses — Neither easy nor difficult to swallow000
Participant Who Received Abemaciclib Tablet: Caregiver Responses — Difficult to swallow000
Participant Who Received Abemaciclib Tablet: Caregiver Responses — Very difficult to swallow000
Participant Who Received Abemaciclib Oral Granules: Participant Responses — Very easy to swallow1——
Participant Who Received Abemaciclib Oral Granules: Participant Responses — Easy to swallow0——
Participant Who Received Abemaciclib Oral Granules: Participant Responses — Neither easy nor difficult to swallow0——
Participant Who Received Abemaciclib Oral Granules: Participant Responses — Difficult to swallow0——
Participant Who Received Abemaciclib Oral Granules: Participant Responses — Very difficult to swallow0——
Participant Who Received Abemaciclib Oral Granules: Caregiver Responses — Very easy to swallow—1—
Participant Who Received Abemaciclib Oral Granules: Caregiver Responses — Easy to swallow—0—
Participant Who Received Abemaciclib Oral Granules: Caregiver Responses — Neither easy nor difficult to swallow—0—
Participant Who Received Abemaciclib Oral Granules: Caregiver Responses — Difficult to swallow—0—
Participant Who Received Abemaciclib Oral Granules: Caregiver Responses — Very difficult to swallow—0—
Participant Who Received Abemaciclib Tablet Dispersed: Participant Responses — Very easy to swallow———
Participant Who Received Abemaciclib Tablet Dispersed: Participant Responses — Easy to swallow———
Participant Who Received Abemaciclib Tablet Dispersed: Participant Responses — Neither easy nor difficult to swallow———
Participant Who Received Abemaciclib Tablet Dispersed: Participant Responses — Difficult to swallow———
Participant Who Received Abemaciclib Tablet Dispersed: Participant Responses — Very difficult to swallow———
Participant Who Received Abemaciclib Tablet Dispersed: Caregiver Responses — Very easy to swallow011
Participant Who Received Abemaciclib Tablet Dispersed: Caregiver Responses — Easy to swallow100
Participant Who Received Abemaciclib Tablet Dispersed: Caregiver Responses — Neither easy nor difficult to swallow000
Participant Who Received Abemaciclib Tablet Dispersed: Caregiver Responses — Difficult to swallow000
Participant Who Received Abemaciclib Tablet Dispersed: Caregiver Responses — Very difficult to swallow000

Adverse events

Collected over Baseline up to end of follow-up (up to 26.37 months). Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Abemaciclib + Irinotecan +Temozolomide15/30 (50%)12/30 (40%)30/30 (100%)
Irinotecan +Temozolomide8/16 (50%)5/15 (33.3%)15/15 (100%)
Most frequent serious events
Showing 10 of 24
Most frequent serious events
EventAbemaciclib + Irinotecan +TemozolomideIrinotecan +Temozolomide
PyrexiaGeneral disorders2/302/15
Abdominal painGastrointestinal disorders3/300/15
DiarrhoeaGastrointestinal disorders3/300/15
Abdominal pain upperGastrointestinal disorders0/301/15
Catheter site infectionInfections and infestations0/301/15
Clostridial infectionInfections and infestations0/301/15
Bone painMusculoskeletal and connective tissue disorders0/301/15
Pleural effusionRespiratory, thoracic and mediastinal disorders0/301/15
Febrile neutropeniaBlood and lymphatic system disorders1/300/15
EnterocolitisGastrointestinal disorders1/300/15
Most frequent other events
Showing 10 of 180
Most frequent other events
EventAbemaciclib + Irinotecan +TemozolomideIrinotecan +Temozolomide
DiarrhoeaGastrointestinal disorders28/3013/15
AnaemiaBlood and lymphatic system disorders19/306/15
Abdominal painGastrointestinal disorders17/308/15
NauseaGastrointestinal disorders17/307/15
VomitingGastrointestinal disorders16/305/15
Platelet count decreasedInvestigations14/302/15
PyrexiaGeneral disorders11/304/15
Neutrophil count decreasedInvestigations10/302/15
HypokalaemiaMetabolism and nutrition disorders10/301/15
Intermenstrual bleedingReproductive system and breast disorders0/91/3

Baseline characteristics

All randomized participants.

Age, Continuous
Age, Continuous(Years)Abemaciclib + Irinotecan +TemozolomideIrinotecan +TemozolomideTotal
Mean16.7 ± 6.717.1 ± 6.816.8 ± 6.6
Sex: Female, Male
Sex: Female, Male(Participants)Abemaciclib + Irinotecan +TemozolomideIrinotecan +TemozolomideTotal
Female9413
Male211233
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Abemaciclib + Irinotecan +TemozolomideIrinotecan +TemozolomideTotal
Hispanic or Latino538
Not Hispanic or Latino201030
Unknown or Not Reported538
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Abemaciclib + Irinotecan +TemozolomideIrinotecan +TemozolomideTotal
American Indian or Alaska Native000
Asian729
Native Hawaiian or Other Pacific Islander000
Black or African American011
White181129
More than one race000
Unknown or Not Reported527
Region of Enrollment
Region of Enrollment(Participants)Abemaciclib + Irinotecan +TemozolomideIrinotecan +TemozolomideTotal
United States325
Japan729
Italy505
France437
Australia101
Germany123
Spain9716
08

Study locations

29 sites
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement.

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: Data are available 6 months after the primary publication and approval of the indication studied in the US and EU, whichever is later. Data will be indefinitely available for requesting.

Access criteria: A research proposal must be approved by an independent review panel and researchers must sign a data sharing agreement.

Data sharing details ↗ · vivli.org

10

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Sep 2022 to primary completion in Jan 2025, 27 months.

Results were first posted in Mar 2026, 1 year 1 month after primary completion.

Of 39 phase 2 interventional studies under Sarcoma, Ewing, half reached primary completion within 55 months of starting (the median), counting those still running; a quarter within 41 and three quarters within 92. This study's 27 months is below that.

Completion moved once since we started tracking on Sep 25, 2026: Dec 2026 → Dec 2027, on Oct 20, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jun 28, 2022
First posted
Jul 1, 2022
StartActual
Sep 20, 2022
Primary completionActual
Jan 15, 2025
CompletionEst.
Dec 2027was Dec 2026
Results first posted
Mar 12, 2026
Last update
Oct 20, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Study completion
Dec 2026→Dec 2027
Oct 20, 2026
Show all 1 update
  1. Oct 20, 2026
    Study completion Dec 2026→Dec 2027
    + 2 other changes: identifiers and verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT05440786
Responsible party
Sponsor
First posted
Jul 1, 2022
Start date
Sep 20, 2022
Primary completion
Jan 15, 2025
Completion
Dec 2027 (estimated)
Results posted
Mar 12, 2026
Last update
Oct 20, 2026

Study contacts

Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 Eastern time (UTC/GMT - 5 hours, EST)
study director · Eli Lilly and Company

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Abemaciclib · Irinotecan · Temozolomide

Start the discussion